Journal
SCIENCE
Volume 369, Issue 6505, Pages 806-+Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abc6284
Keywords
-
Categories
Funding
- Ragon Institute of MGH, MIT, and Harvard
- Mark and Lisa Schwartz Foundation
- Beth Israel Deaconess Medical Center
- Massachusetts Consortium on Pathogen Readiness (MassCPR)
- Janssen Vaccines Prevention BV
- National Institutes of Health [OD024917, AI129797, AI124377, AI128751, AI126603, AI007151, AI146779, AI121394, AI139538, 272201700036I-0-759301900131-1, AI100625, AI110700, AI132178, AI149644, AI108197]
- Burroughs Wellcome Fund Postdoctoral Enrichment Program Award
Ask authors/readers for more resources
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV- 2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS- CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log(10) reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available